瑞格列奈治疗初发2型糖尿病200例疗效观察

Repaglinide for treatment of newly diagnosed type 2 diabetes mellifus

摘要: 目的: 观察瑞格列奈治疗初发2型糖尿病的疗效。方法: 对200例初发2型糖尿病患者在饮食控制及运动治疗基础上,给予瑞格列奈1 mg,每天3次,饭前服用,观察16周。分别于治疗8周及16周后测量体重指数、血脂、空腹血糖、餐后血糖、糖基化血红蛋白、空腹胰岛素水平。结果: 治疗16周后患者的空腹血糖、餐后2 h血糖、糖基化血红蛋白水平均明显下降(P <0.01)。结论: 瑞格列奈能有效控制2型糖尿病患者的血糖,不良反应少,且低血糖发生率低。

Abstract: Objective: To observe the efficacy of repaglinide in treatment of newly diagnosed type 2 diabetes mellitus. Methods: Two hundred patients who were newly diagnosed to have type 2 diabetes mellifus were administered repaglinide 1.0 mg 3 times a day before meals in addition to the therapy of diet-control and adequate exercise. And the effect was observed in the following 16 weeks. The BMI,blood fat,fasting blood glucose,blood glucose 2 hours after meals,HbA1C and fasting insulin at 8 weeks and 16 weeks after the therapy were detected. Results: After 16 weeks of treatment,the fasting blood glucose,blood glucose 2 hours after meals and HbA1C were significantly decreased (P < 0.01). Conclusions: Repaglinide may effectively control the blood glucose of patients with type 2 diabetes with few adverse reactions and a low incidence of hypoglycemia.